Novartis Financials

Market Capitalization CHF192.53 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	19.26
Forward PE	15.77
Price to Sales TTM	CHF3.62
Price to Book MRQ	CHF4.98
Enterprise to Revenue	4.00
Enterprise to EBITDA	9.63

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	24.16%
Operating Margin	35.40%
Return on Assets TTM	11.42%
Return on Equity TTM	32.89%

Income Statement

Revenue TTM	CHF42,077,845,371
Revenue per Share TTM	CHF26.62
Quarterly Revenue Growth	12.40%
Gross Profit TTM	CHF31,844,980,236
EBITDA	CHF21,882,000,000
Net Income to Common TTM	CHF10,166,454,095
Diluted EPS TTM	CHF5.06
Quarterly Earnings Growth YoY	34.20%

Balance Sheet

Total Cash MRQ	CHF5,642,583,662
Total Cash per Share MRQ	CHF3.64
Total Debt MRQ	CHF
Total Debt to Equity MRQ	81.32
Current Ratio MRQ	0.79
Book Value per Share MRQ	CHF19.58

Cash Flow

Operating Cash Flow TTM	CHF15,020,799,010
Levered Free Cash Flow TTM	CHF10,982,066,923

NOVN Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	1,975,089,248
Float Shares	1,867,188,567
Avg 10 Volume	3,259,356
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.04%
% Held by Institutions	39.86%

Stock Price Summary

Beta	0.53
Fifty Two Week Low	CHF81.10
Fifty Two Week High	CHF102.72
Fifty Two Week Change	1.39%
Day 50 MA	CHF94.12
Day 200 MA	CHF94.10

Dividends and Splits

Forward Annual Dividend Rate	CHF14.00
Forward Annual Dividend Yield	14.28%
Trailing Annual Dividend Rate	CHF3.50
Trailing Annual Dividend Yield	3.57%
Payout Ratio	62.27%
Dividend Date	2025-03-13
Ex Dividend Date	2025-03-11
Last Split Factor
Last Split Date	2023-10-04